Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2003 Feb;28(1):39-49.
doi: 10.1007/BF02970130.

Justification for antioxidant preconditioning (or how to protect insulin-mediated actions under oxidative stress)

Affiliations
Review

Justification for antioxidant preconditioning (or how to protect insulin-mediated actions under oxidative stress)

A Orzechowski. J Biosci. 2003 Feb.

Abstract

Insulin resistance is characterized by impaired glucose utilization in the peripheral tissues, accelerated muscle protein degradation, impaired antioxidant defences and extensive cell death. Apparently, both insulin and IGF-1 at physiological concentrations support cell survival by phosphatidylinositol 3 kinase-dependent and independent mechanisms. Postprandial hyperglycemia and hyperinsulinemia are found in insulin resistance, which accompanies the so-called noninsulin dependent diabetes mellitus (diabetes type 2). Evidence also indicates that increased susceptibility of muscle cells and cardiomycoytes to oxidative stress is among the harmful complications of insulin resistance and diabetes. Limited knowledge showing benefits of preconditioning with anti- oxidants (vitamin C, E, a-lipoic acid, N-acetylcysteine) in order to protect insulin action under oxidative stress prompted the author to discuss the theoretical background to this approach. It should be stressed that antioxidant preconditioning is relevant to prevention of both diabetes- and insulin resistance-associated side-effects such as low viability and cell deletion. Furthermore, antioxidant conditioning promises to provide higher efficacy for clinical applications in myoblast transfer therapy and cardiomyoplasty.

PubMed Disclaimer

Similar articles

References

    1. Diabetes. 1996 Dec;45(12):1798-804 - PubMed
    1. Am J Physiol. 1997 Jul;273(1 Pt 1):E68-76 - PubMed
    1. Cell. 2000 Oct 13;103(2):211-25 - PubMed
    1. Thromb Haemost. 1999 Aug;82(2):810-7 - PubMed
    1. Biol Chem. 1997 Jul;378(7):609-16 - PubMed

LinkOut - more resources

  NODES
twitter 2